Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Vir Biotechnology, Inc.

Get SEC filing alerts via email and in your feed for Vir Biotechnology, Inc.

VIR

Vir Biotechnology, Inc.

About Vir Biotechnology, Inc.

Vir Biotechnology, Inc. is a biopharmaceutical company focused on developing therapies for infectious diseases and cancer. Its core activities include discovering and engineering antibodies, T-cell engagers, and siRNA treatments targeting hepatitis B, hepatitis delta, HIV, and solid tumors. Leveraging immunology, AI, and proprietary platforms, it aims to create innovative, targeted, and safer medicines to address high unmet medical needs worldwide.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Vir Biotechnology, Inc.

1
1
Vir Biotechnology, Inc. Vir Biotechnology Reports $125.7 Million Net Loss and Decline in Revenues for Q1 2026

Via official filing (AI summary) | 30 days ago | 0 comments

2
1
Vir Biotechnology, Inc. Vir Biotechnology Reports $438M Net Loss and $68.6M Revenue for 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Vir Biotechnology, Inc. Vir Biotechnology Reports $163.1 Million Net Loss in Q3 2025, Revenue Declines Significantly

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Vir Biotechnology, Inc. Vir Biotechnology Reports 60% Revenue Decline in Q2 2025, Net Loss of $111 Million

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Vir Biotechnology, Inc. Vir Biotechnology Reports 95% Revenue Decline and $121M Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Vir Biotechnology, Inc. Vir Biotechnology Reports Decrease in Revenues and Net Loss in Latest Quarter, Initiates Restructuring Plan

Via official filing (AI summary) | over 1 year ago | 0 comments